

Complement activity and complement regulatory gene thrombosis in APS and CAPS

Blood

135, 239-251

DOI: [10.1182/blood.2019003863](https://doi.org/10.1182/blood.2019003863)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. <i>Annals of Hematology</i> , 2020, 99, 1953-1965.	1.8	54
2	Coagulopathy in COVID-19: Focus on vascular thrombotic events. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 146, 32-40.	1.9	49
3	Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 597-600.	2.1	8
4	Ex vivo assays to detect complement activation in complementopathies. <i>Clinical Immunology</i> , 2020, 221, 108616.	3.2	7
5	Understanding and Preventing Placenta-Mediated Pregnancy Complications. <i>Hamostaseologie</i> , 2020, 40, 356-363.	1.9	12
6	Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. <i>Nature Reviews Rheumatology</i> , 2020, 16, 581-589.	8.0	203
7	Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab. <i>Blood</i> , 2020, 136, 2473-2477.	1.4	22
8	Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Lancet Haematology</i> , 2020, 7, e613-e623.	4.6	6
9	COVID-19 Infection and High Intracoronary Thrombus Burden. <i>Cardiovascular Revascularization Medicine</i> , 2021, 28, 82-87.	0.8	2
10	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	1.6	80
11	Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. <i>Blood</i> , 2020, 136, 2080-2089.	1.4	283
12	Acute dilated cardiomyopathy in the setting of catastrophic antiphospholipid syndrome and thrombotic microangiopathy: A case series and review. <i>EJHaem</i> , 2020, 1, 44-50.	1.0	1
13	Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2935.	2.4	8
14	Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses. <i>Current Hypertension Reports</i> , 2020, 22, 63.	3.5	121
15	16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. <i>Lupus</i> , 2020, 29, 1594-1600.	1.6	26
16	Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily. <i>British Journal of Haematology</i> , 2020, 189, e227-e230.	2.5	160
17	Antiphospholipid syndrome. <i>Translational Research</i> , 2020, 225, 70-81.	5.0	44
18	Microvascular thrombosis: experimental and clinical implications. <i>Translational Research</i> , 2020, 225, 105-130.	5.0	62

#	ARTICLE	IF	CITATIONS
19	More about complement in the antiphospholipid syndrome. <i>Blood</i> , 2020, 136, 1456-1459.	1.4	5
20	Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment. <i>Current Cardiology Reports</i> , 2020, 22, 52.	2.9	47
21	Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature. <i>Lupus</i> , 2020, 29, 631-639.	1.6	13
22	Distinct genetic profile with recurrent population-specific missense variants in Korean adult atypical hemolytic uremic syndrome. <i>Thrombosis Research</i> , 2020, 194, 45-53.	1.7	4
23	Thrombotic microangiopathy, DIC-syndrome and COVID-19: link with pregnancy prothrombotic state. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 2536-2544.	1.5	13
24	Catastrophic antiphospholipid syndrome: is life-long anticoagulation therapy required?. <i>Clinical Rheumatology</i> , 2020, 39, 2115-2119.	2.2	2
25	Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. <i>Translational Research</i> , 2020, 220, 1-13.	5.0	1,843
26	Taken the wrong way, a complement becomes catastrophic. <i>Blood</i> , 2020, 135, 233-234.	1.4	2
27	Compliments to complement blockade for TA-TMA. <i>Blood</i> , 2020, 135, 981-983.	1.4	3
28	Pediatric Catastrophic Antiphospholipid Syndrome Successfully Treated with Eculizumab. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 640-642.	5.6	1
29	Thrombocytopeny and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. <i>Nature Reviews Cardiology</i> , 2021, 18, 194-209.	13.7	304
30	Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 607-616.	3.8	45
31	How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Blood</i> , 2021, 137, 299-309.	1.4	15
32	Demystifying COVID-19 lung pathology: A clinicopathological study of postmortem core needle biopsy. <i>Lung India</i> , 2021, 38, 343.	0.7	3
33	Clinical characteristics, inflammation and coagulation status in patients with immunological disease-related chronic cerebrospinal venous insufficiency. <i>Annals of Translational Medicine</i> , 2021, 9, 236-236.	1.7	3
34	A Review of Complement Activation in SLE. <i>Current Rheumatology Reports</i> , 2021, 23, 16.	4.7	71
35	Coronavirus disease 2019 (COVID-19) and autoimmunity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 5-30.	1.0	28
37	Complement in Sickle Cell Disease: Are We Ready for Prime Time?. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 177-187.	1.7	8

#	ARTICLE	IF	CITATIONS
38	Significant non-existence of sequences in genomes and proteomes. <i>Nucleic Acids Research</i> , 2021, 49, 3139-3155.	14.5	15
39	Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome. <i>Blood</i> , 2021, 137, 2989-2992.	1.4	4
40	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. <i>Current Rheumatology Reports</i> , 2021, 23, 45.	4.7	9
41	Genetic justification of severe COVID-19 using a rigorous algorithm. <i>Clinical Immunology</i> , 2021, 226, 108726.	3.2	47
42	New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2021, 8, 93-99.	0.6	6
43	Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19. <i>Clinical Immunology</i> , 2021, 226, 108716.	3.2	41
44	Small Bowel Necrosis Associated with Catastrophic Antiphospholipid Syndrome: A Case Report. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2021, 77, 294-299.	0.4	1
45	Skin manifestations as potential symptoms of diffuse vascular injury in critical COVID-19 patients. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 1266-1276.	1.3	25
46	Natural products provide a new perspective for anti-complement treatment of severe COVID-19: a review. <i>Chinese Medicine</i> , 2021, 16, 67.	4.0	9
47	The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation. <i>Journal of Clinical Medicine</i> , 2021, 10, 3034.	2.4	12
48	Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease. <i>Pharmaceuticals</i> , 2021, 14, 751.	3.8	13
49	Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing. <i>Blood Reviews</i> , 2021, 48, 100805.	5.7	12
50	Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2335-2347.	3.8	27
51	Complement dysregulation is associated with severe COVID-19 illness. <i>Haematologica</i> , 2022, 107, 1095-1105.	3.5	34
52	Complement and the prothrombotic state. <i>Blood</i> , 2022, 139, 1954-1972.	1.4	15
53	An allosteric redox switch in domain V of Î²2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition. <i>Journal of Biological Chemistry</i> , 2021, 297, 100890.	3.4	10
54	Early use of eculizumab for catastrophic antiphospholipid syndrome. <i>British Journal of Haematology</i> , 2022, 196, .	2.5	7
55	Successful Treatment of Catastrophic Antiphospholipid Syndrome Using Rituximab: Case Report and Review of the Literature. <i>Medicina (Lithuania)</i> , 2021, 57, 912.	2.0	8

#	ARTICLE	IF	CITATIONS
56	Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond. <i>Blood</i> , 2022, 139, 3571-3582.	1.4	33
57	The Effect of Various Types of Anticoagulant Therapy on the Reduction of Mortality in COVID-19. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 268-278.	0.6	0
58	Complementopathies and precision medicine. <i>Journal of Clinical Investigation</i> , 2020, 130, 2152-2163.	8.2	70
59	Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 353-367.	1.0	33
62	A Guide to Differentiating Thrombotic Microangiopathies Through a Case of Catastrophic Antiphospholipid Syndrome. <i>AJSP Review and Reports</i> , 2020, 25, 266-269.	0.1	1
63	Thrombotic storm, hemostasis disorders and thromboinflammation in COVID-19. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 499-514.	0.5	8
64	Report on effective treatment and genetic predisposition in two children with refractory probable catastrophic antiphospholipid syndrome. <i>Thrombosis Research</i> , 2021, 208, 117-120.	1.7	1
65	Pathophysiology of Antiphospholipid Syndrome. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1085-1095.	3.4	7
67	Complement-related thrombosis. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 695-707.	0.1	0
68	Eculizumab for refractory thrombosis in antiphospholipid syndrome. <i>Blood Advances</i> , 2022, 6, 1271-1277.	5.2	9
69	Catastrophic antiphospholipid syndrome presented with coronary thrombosis, renal impairment, and suspected diffuse alveolar hemorrhage treated with rituximab biosimilar (CT-P10). <i>European Journal of Inflammation</i> , 2022, 20, 205873922110508.	0.5	0
70	Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 675.	2.4	33
71	Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. <i>Seminars in Immunopathology</i> , 2022, 44, 347-362.	6.1	67
72	Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 852777.	2.4	8
73	All catastrophes are not catastrophic antiphospholipid syndrome. <i>American Journal of Hematology</i> , 2022, 97, 968-974.	4.1	0
74	The complement system and autoimmune diseases. <i>Chronic Diseases and Translational Medicine</i> , 2022, 8, 184-190.	1.2	3
75	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). <i>Lupus</i> , 2021, 30, 2276-2285.	1.6	21
76	Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. <i>Paediatric Drugs</i> , 2022, 24, 13-27.	3.1	5

#	ARTICLE	IF	CITATIONS
77	Two cases of refractory pediatric antiphospholipid syndrome. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29506.	1.5	1
78	An Update on Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2021, 23, 84.	4.7	20
79	Ex Vivo Test for Measuring Complement Attack on Endothelial Cells: From Research to Bedside. <i>Frontiers in Immunology</i> , 2022, 13, 860689.	4.8	9
80	Cardiovascular complications of catastrophic antiphospholipid syndrome: a case report and review of literature. <i>European Heart Journal - Case Reports</i> , 2022, 6, .	0.6	2
81	Skin necrosis in COVID-19 patients: complication of therapy or one of clinical and pathological mechanisms of viral infection?. <i>International Journal of Research in Dermatology</i> , 2022, 8, 419.	0.1	0
82	Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. <i>Journal of Clinical Medicine</i> , 2022, 11, 3355.	2.4	4
83	The clinical significance of low complement levels in patients with catastrophic antiphospholipid syndrome: A descriptive analysis of 73 patients from the "Catastrophic antiphospholipid syndrome registry". <i>Lupus</i> , 2022, 31, 1218-1225.	1.6	4
84	Update in Hyperferritinemic Syndromes: Recognition and Management - A Scoping Review. , 2022, 1, .		1
85	C5 inhibition allows continued antineoplastic therapy in cancer and chemotherapy associated thrombotic microangiopathy. <i>Blood Advances</i> , 0, , .	5.2	1
86	Minimal role for the alternative pathway in complement activation by HIT immune complexes. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2656-2665.	3.8	3
87	Renal and vascular outcomes in patients with isolated antiphospholipid syndrome nephropathy. <i>Journal of Autoimmunity</i> , 2022, 132, 102889.	6.5	4
88	Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 589-600.	4.2	3
89	Contributions of animal models to mechanistic understandings of antibody-dependent disease and roles of the amplification loop. <i>Immunological Reviews</i> , 0, , .	6.0	3
90	Hemostatic system and COVID-19 crosstalk: A review of the available evidence. <i>World Journal of Methodology</i> , 2022, 12, 331-349.	3.5	1
91	Emerging Therapies in Antiphospholipid Syndrome. <i>Transfusion Medicine Reviews</i> , 2022, 36, 195-203.	2.0	1
92	Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis. <i>Blood Reviews</i> , 2023, 58, 101015.	5.7	5
93	Epidemiology and prevention of venous thromboembolism. <i>Nature Reviews Cardiology</i> , 2023, 20, 248-262.	13.7	52
94	Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12819.	4.1	4

#	ARTICLE	IF	CITATIONS
95	COVID-19 and antiphospholipid antibodies. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101402.	1.7	12
97	Complement activation predicts negative outcomes in COVID-19: The experience from Northern Italian patients.. <i>Autoimmunity Reviews</i> , 2023, 22, 103232.	5.8	6
98	IL-33 and the Cytokine Storm in COVID-19: From a Potential Immunological Relationship towards Precision Medicine. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14532.	4.1	10
99	Renal Thrombotic Microangiopathy: A Review. <i>American Journal of Kidney Diseases</i> , 2023, 81, 591-605.	1.9	23
100	Differentiating and Managing Rare Thrombotic Microangiopathies During Pregnancy and Postpartum. <i>Obstetrics and Gynecology</i> , 2023, 141, 85-108.	2.4	4
101	Antiphospholipid Syndrome in Renal Allograft Recipientsâ€”A Long-Term Multicenter Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 667.	2.4	1
102	Complementâ€”driven hemolytic uremic syndrome. <i>American Journal of Hematology</i> , 2023, 98, .	4.1	4
103	Complement biology for hematologists. <i>American Journal of Hematology</i> , 2023, 98, .	4.1	6
104	Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression. <i>Drugs</i> , 2023, 83, 287-298.	10.9	7
105	Pathway-driven rare germline variants associated with transplant-associated thrombotic microangiopathy (TA-TMA). <i>Thrombosis Research</i> , 2023, 225, 39-46.	1.7	0
107	A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3169.	4.1	32
108	Immune Thrombocytopenia Could be an Independent Clinical Phenotype of Antiphospholipid Syndrome: A Prospective Cohort Study. <i>Rheumatology and Therapy</i> , 2023, 10, 649-658.	2.3	0
109	Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. <i>BMJ</i> , The, 0, , e069717.	6.0	33
110	Case 8-2023: A 71-Year-Old Woman with Refractory Hemolytic Anemia. <i>New England Journal of Medicine</i> , 2023, 388, 1032-1041.	27.0	0
111	Hospitalized patients with positive antiphospholipid antibodies who have low complement levels are at increased risk for deathâ€”a retrospective cohort study. <i>Lupus</i> , 0, , 096120332311640.	1.6	0
112	The Antiphospholipid Syndrome. , 2023, , 225-239.		0
114	SARS CoV-2 infection as a risk factor of preeclampsia and pre-term birth. An interplay between viral infection, pregnancy-specific immune shift and endothelial dysfunction may lead to negative pregnancy outcomes. <i>Annals of Medicine</i> , 2023, 55, .	3.8	2
115	High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0

#	ARTICLE	IF	CITATIONS
116	An update on the biologics for the treatment of antiphospholipid syndrome. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
117	How to approach acute thrombosis and thrombocytopenia. <i>Clinical Medicine</i> , 2023, 23, 234-241.	1.9	4
118	Role of Î²2â€¦glycoprotein I in the pathogenesis of the antiphospholipid syndrome. <i>Rheumatology & Autoimmunity</i> , 0, , .	0.8	0
119	Complement therapeutics are coming of age in rheumatology. <i>Nature Reviews Rheumatology</i> , 2023, 19, 470-485.	8.0	2
120	Catastrophic antiphospholipid syndrome immediately after coronary angiography: the unexpected complication. <i>Blood Coagulation and Fibrinolysis</i> , 2023, 34, 239-243.	1.0	0
121	Overview on the Link Between the Complement System and Auto-Immune Articular and Pulmonary Disease. <i>Open Access Rheumatology: Research and Reviews</i> , 0, Volume 15, 65-79.	1.6	2
122	Research Progress on Risk Factors for Acute Pulmonary Embolism. <i>Advances in Clinical Medicine</i> , 2023, 13, 8512-8518.	0.0	0
123	Complement and platelets: prothrombotic cell activation requires membrane attack complexâ€¦induced release of danger signals. <i>Blood Advances</i> , 2023, 7, 6367-6380.	5.2	5
125	Transcriptome analysis suggests a central role for complement and C5aR1 in neutrophil activation in APS. <i>Thrombosis Research</i> , 2023, 230, 94-97.	1.7	0
126	Modern concept of autoimmunity in rheumatology. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2023, 61, 397-420.	1.0	6
127	Evaluating complement dysregulation in livedoid vasculopathy using a functional assay. <i>Blood Advances</i> , 0, , .	5.2	0
128	Severe cutaneous necrosis in antiphospholipid syndrome. <i>American Journal of Hematology</i> , 2023, 98, .	4.1	0
129	The role of C5a receptors in autoimmunity. <i>Immunobiology</i> , 2023, 228, 152413.	1.9	1
130	Covid and Ulceration. , 2023, , 161-177.		0
131	Antiphospholipid antibody carriers and patients with quiescent antiphospholipid syndrome show persistent subclinical complement activation. <i>Rheumatology</i> , 0, , .	1.9	0
133	Anti-phospholipid autoantibodies in human diseases. <i>Clinical Immunology</i> , 2023, 256, 109803.	3.2	1
134	Complement biomarkers in the antiphospholipid syndrome â€¦ Approaches to quantification and implications for clinical management. <i>Clinical Immunology</i> , 2023, 257, 109828.	3.2	0
135	Catastrophic Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2024, 25, 668.	4.1	1

#	ARTICLE	IF	CITATIONS
136	Risk factors of first thrombosis in obstetric antiphospholipid syndrome. <i>Lupus Science and Medicine</i> , 2024, 11, e001044.	2.7	0
137	<i><i>Not So Benign</i> Antiphospholipid Antibody Syndrome: Clots, Complement, and Catastrophe!.</i> , 2024, 21, .		0
138	An immunogenomic exome landscape of triple positive primary antiphospholipid patients. <i>Genes and Immunity</i> , 2024, 25, 108-116.	4.1	0
139	Platelets and Thrombotic Antiphospholipid Syndrome. <i>Journal of Clinical Medicine</i> , 2024, 13, 741.	2.4	0
140	Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?. <i>Rheumatology</i> , 2024, 63, SI4-SI13.	1.9	2
141	What we know and what we donâ€™t know about catastrophic antiphospholipid syndrome. <i>Rheumatology</i> , 2024, 63, SI46-SI53.	1.9	1
142	Update on antiphospholipid syndrome. <i>Rheumatology</i> , 2024, 63, SI1-SI3.	1.9	0
143	Eculizumab therapy and complement regulation in a case of resistant catastrophic antiphospholipid syndrome. <i>BMJ Case Reports</i> , 2024, 17, e254449.	0.5	0
144	Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2024, 62, 32-54.	1.0	0
145	Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. <i>Antibodies</i> , 2024, 13, 21.	2.5	0